U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. CDER Conversations
  1. News & Events for Human Drugs

CDER Conversations

Discussions with key Center for Drug Evaluation and Research (CDER) leadership about important regulatory and policy issues

Latest CDER Conversations

View all

CDER Conversation with Kevin Bugin
CDER Launches a Center for Clinical Trial Innovation

Kevin Bugin, PhD, lead for C3TI and deputy director of operations in the Office of New Drugs (OND), explains the purpose of C3TI, the importance of clinical trial innovation, and ways in which C3TI can advance public health.

Read more

CDER Conversation with Chistopher Diamant
Patient Medication Information: A 2023 Proposed Rule to Help Patients Understand Their Prescription Medication Information

Christopher Diamant, J.D., regulatory counsel in CDER’s Office of Medical Policy, discusses how the proposed rule regarding PMI could help provide patients with clear instructions, ultimately helping them take their prescription medications as intended

Read more

CDER Conversation Gerald Dal Pan Headshot
Understanding CDER’s Postmarket Safety Surveillance Programs and Public Data

Gerald J. Dal Pan, M.D., M.H.S., Director of CDER’s Office of Surveillance and Epidemiology (OSE), discusses current priorities to develop and implement processes needed to support efficient and effective postmarket safety.

Read more

CDER Conversation with Liang Zhao and Mehul Mehta
Setting and Implementing Standards for Narrow Therapeutic Index Drugs

Our experts discuss how CDER helps ensure the dosage range of narrow therapeutic index (NTI) drugs falls within a safe and effective therapeutic window, and the challenges and opportunities in developing NTI generic drugs.

Read more

All CDER Conversations






View archived CDER Conversations (2014-2019)


Back to Top